Startup
Every investor coverage indicates participated in a round Longas raised.
| Investor | Rounds | Invested |
|---|---|---|
| Dr Catherine Burke | Unnamed stage | - |
| Dr Stephen Thompson | Unnamed stage | - |
| Medical Research Commercialisation Fund (MRCF) | Unnamed stage | - |
| Nick McCooke | Unnamed stage | - |
| Professor Aaron Darling | Unnamed stage | - |
| Professor Ian Charles | Unnamed stage | - |
Investors whose own portfolio pages list Longas, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
Companies Longas acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Longas. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian genomics spin-out Longas has come out of stealth with technology that extends DNA sequencing read length, backed by the MRCF and its founders, and appoints Solexa's founding chief executive Nick McCooke as CEO.
A university spin-out launches with venture and founder backing, introducing a technology that extends DNA sequencing read lengths, and appointing a new chief executive to commercialise it.